Inova Translational Medicine Institute’s Study Featured in Time Magazine
Inova Translational Medicine Institute (ITMI) is Inova’s visionary initiative to bring personalized medicine to Northern Virginia and the world. It is leading the transformation of healthcare from a reactive to a predictive model using technological innovation, pioneering research and sophisticated information management.
The goal is to provide the right treatment for the right patient at the right time, and ultimately prevent disease in the first place. The long-term work of ITMI will enable Inova to successfully and quickly translate advances from genomics (the study of genes and their function) and the molecular sciences to patients, optimizing individual health and well-being.
Personalized medicine: the next frontier
Personalized medicine applies very sophisticated technologies to distinguish the unique genetic code that makes us who we are, determine whether we are at increased risk of developing a particular disease, find the most effective ways for our bodies to handle that disease, and perhaps even pinpoint ways to avoid disease in the first place.
Characaterizing a patient’s complete genetic code – known as genomic sequencing – will allow doctors to diagnose disease earlier and manage it more specifically. Treatment will be tailored to the individual rather than the illness. Ultimately, biomedical researchers hope to be able to use a patient’s genome to predict his or her risk of developing a particular disease and develop the right therapies to prevent it.
The transformation begins with research
ITMI eventually hopes to assemble the world’s largest amount of Whole Genome Sequence data in a single database to provide highly targeted information for personalized healthcare and to spur biomedical research worldwide.
The Institute is well on its way. Already researchers have generated 1,500 complete DNA (whole genome) sequences as part of the first clinical study aimed at unraveling the mysteries of pre-term birth. The goal is even loftier for the next study – a comprehensive genetic look at 2,500 families in Fairfax County, which will yield 20,000 whole genome sequences over the next two years.